On the potential use of flavonoids in the treatment and prevention of pancreatic cancer

In Vivo

Volumn 19, Issue 1, 2005, Pages 61-68

  Roginsky, Alexandra B ^a   Ujiki, Michael B ^a   Ding, Xian Zhong ^a   Adrian, Thomas E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemoprevention; Flavonoids; Pancreatic cancer; Review

Indexed keywords

APIGENIN; BAICALEIN; CATECHIN; CISPLATIN; COUMESTROL; DAIDZEIN; DOCETAXEL; EPICATECHIN; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; EQUOL; FLAVANOL DERIVATIVE; FLAVONOID; FLAVOPIRIDOL; GALLOCATECHIN; GEMCITABINE; GENISTEIN; HERBIMYCIN A; ISOFLAVONE DERIVATIVE; LAVENDUSTIN A; LIPOXYGENASE; LUTEOLIN; METHYLNITROSOUREA; POLYPHENOL DERIVATIVE; PROSTAGLANDIN SYNTHASE; QUERCETIN; RESVERATROL; RUTOSIDE; SCUTELLARIA BAICALENSIS EXTRACT; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER SURVIVAL; DATA ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MEDICAL LITERATURE; NONHUMAN; PANCREAS CANCER; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

EID: 16244372408     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E and Thun MJ: Cancer statistics, 2003. CA Cancer J Clin 53: 5-26, 2003.
2. Von Hoff DD and Bearss D: New drugs for patients with pancreatic cancer. Curr Opin Oncol 14: 621-7, 2002.
3. Gollin MA: New rules for natural products research. Nat Biotechnol 17: 921-2, 1999.
4. Beecher GR: Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr 133: 3248S-3254S, 2003.
5. Di Carlo G, Mascolo N, Izzo AA and Capasso F: Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 65 337-53, 1999.
6. Birt DF, Hendrich S and Wang W: Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther 90: 157-77, 2001.
7. Hertog MG, Feskens EJ, Hollman PC, Katan MB and Kromhout D: Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342: 1007-11, 1993.
8. Hertog MG, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F et al: Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch Intern Med 155: 381-6, 1995.
9. Knekt P, Jarvinen R, Reunanen A and Maatela J: Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 312: 478-81, 1996.
10. Sato M, Ray PS, Maulik G, Maulik N, Engelman RM, Bertelli AA et al: Myocardial protection with red wine extract. J Cardiovasc Pharmacol 35: 263-8, 2000.
11. Ray PS, Maulik G, Cordis GA, Bertelli AA, Bertelli A and Das DK: The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 27: 160-9, 1999.
12. Erdman JW Jr: AHA Science Advisory: Soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition Committee of the AHA. Circulation 102: 2555-9, 2000.
13. Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA Jr, Stampfer MJ, Willett WC et al: Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 348 109-18, 2003.
14. Casagrande F and Darbon JM: p21CIP1 is dispensable for the G2 arrest caused by genistein in human melanoma cells. Exp Cell Res 258 101-8, 2000.
15. Wei H, Saladi R, Lu Y, Wang Y, Palep SR, Moore J et al: Isoflavone genistein: photoprotection and clinical implications in dermatology. J Nutr 133: 3811S-3819S, 2003.
16. Chang KL, Kung ML, Chow NH and Su SJ: Genistein arrests hepatoma cells at G2/M phase: involvement of ATM activation and upregulation of p21waf1/cip1 and Wee1. Biochem Pharmacol 67: 717-26, 2004.
17. Shao ZM, Alpaugh ML, Fontana JA and Barsky SH: Genistein inhibits proliferation similarly in estrogen receptor-positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis. J Cell Biochem 69: 44-54, 1998.
18. Farivar RS, Gardner-Thorpe J, Ito H, Arshad H, Zinner MJ, Ashley SW et al: The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines. J Surg Res 115: 219-25, 2003.
19. Lutz MP, Esser IB, Flossmann-Kast BB, Vogelmann R, Luhrs H, Friess H et al: Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 243: 503-8, 1998.
20. Douziech N, Calvo E, Laine J and Morisset J: Activation of MAP kinases in growth responsive pancreatic cancer cells. Cell Signal 11: 591-602, 1999.
21. Morisset J, Douziech N, Rydzewska G, Buscail L and Rivard N: Cell signalling pathway involved in PACAP-induced AR4-2J cell proliferation. Cell Signal 7: 195-205, 1995.
22. Douziech N, Lajas A, Coulombe Z, Calvo E, Laine J and Morisset J: Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines. Endocrine 9 171-83, 1998.
23. Ding XZ, Iversen P, Cluck MW, Knezetic JA and Adrian TE: Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem Biophys Res Commun 261: 218-23, 1999.
24. Ding XZ, Tong WG and Adrian TE: 12-Lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation. Int J Cancer 94: 630-6, 2001.
25. Warburg OH and Dickens F: Berlin. Kaiser Wilhelm-Institut für Biologic. The Metabolism of Tumours; Investigations from the Kaiser Wilhelm Institute for Biology, Berlin-Dahlem. London, Constable; 1930.
26. Boros LG, Bassilian S, Lim S and Lee WN: Genistein inhibits nonoxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: a new mechanism of controlling tumor growth. Pancreas 22: 1-7, 2001.
27. Bian X, McAllister-Lucas LM, Shao F, Schumacher KR, Feng Z, Porter AG et al: NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 276: 48921-9, 2001.
28. Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK and Cheng AL: Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol 63: 1423-30, 2002.
29. Lin ZP, Boller YC, Amer SM, Russell RL, Pacelli KA, Patierno SR et al: Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance. Cancer Res 58: 3059-65, 1998.
30. Wang CY, Cusack JC Jr, Liu R and Baldwin AS Jr: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-7, 1999.
31. Reed JC: Apoptosis-targeted therapies for cancer. Cancer Cell 3: 17-22, 2003.
32. Li Y, Ellis KL, Ali S, El-Rayes BF, Nedeljkovic-Kurepa A, Kucuk O et al: Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line. Pancreas 28: e90-5, 2004.
33. Lee LT, Huang YT, Hwang JJ, Lee PP, Ke FC, Nair MP et al Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res 22: 1615-27, 2002.
34. Boros LG, Lee WN and Go VL: A metabolic hypothesis of cell growth and death in pancreatic cancer. Pancreas 24: 26-33, 2002.
35. Mouria M, Gukovskaya AS, Jung Y, Buechler P, Hines OJ, Reber HA et al: Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer 98: 761-9, 2002.
36. Buchler P, Reber HA, Buchler M, Shrinkante S, Buchler MW, Friess H et al: Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 26: 56-64, 2003.
37. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U and Vaupel P: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56: 4509-15, 1996.
38. Moulder JE and Rockwell S: Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 5: 313-41, 1987.
39. Buchler P, Reber HA, Buchler MW, Friess H, Lavey RS and Hines OJ: Antiangiogenic activity of genistein in pancreatic carcinoma cells is mediated by the inhibition of hypoxia-inducible factor-1 and the down-regulation of VEGF gene expression. Cancer 100: 201-10, 2004.
40. Buchler P, Gukovskaya AS, Mouria M, Buchler MC, Buchler MW, Friess H et al: Prevention of metastatic pancreatic cancer growth in vivo by induction of apoptosis with genistein, a naturally occurring isoflavonoid. Pancreas 26: 264-73, 2003.
41. Lian JP, Word B, Taylor S, Hammons GJ and Lyn-Cook BD: Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. Anticancer Res 24: 133-7, 2004.
42. Reinli K and Block G: Phytoestrogen content of foods - a compendium of literature values. Nutr Cancer 26: 123-48, 1996.
43. Lyn-Cook BD, Stottman HL, Yan Y, Blann E, Kadlubar FF and Hammons GJ: The effects of phytoestrogens on human pancreatic tumor cells in vitro. Cancer Lett 142: 111-9, 1999.
44. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549-54, 1988.
45. Barotto NN, Lopez CB, Eynard AR, Fernandez Zapico ME and Valentich MA: Quercetin enhances pretumorous lesions in the NMU model of rat pancreatic carcinogenesis. Cancer Lett 129: 1-6, 1998.
46. Guo JM, Kang GZ, Xiao BX, Liu DH and Zhang S: Effect of daidzein on cell growth, cell cycle, and telomerase activity of human cervical cancer in vitro. Int J Gynecol Cancer 14: 882-8, 2004.
47. Guo JM, Xiao BX, Liu DH, Grant M, Zhang S, Lai YF et al Biphasic effect of daidzein on cell growth of human colon cancer cells. Food Chem Toxicol 42: 1641-6, 2004.
48. Guo JM, Xiao BX, Dai DJ, Liu Q and Ma HH: Effects of daidzein on estrogen-receptor-positive and negative pancreatic cancer cells in vitro. World J Gastroenterol 10: 860-3, 2004.
49. Schultz J: Resveratrol may be a powerful cancer-fighting ally. J Natl Cancer Inst 96: 1497-8, 2004.
50. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-20, 1997.
51. Bhat KP and Pezzuto JM: Cancer chemopreventive activity of resveratrol. Ann N Y Acad Sci 957: 210-29, 2002.
52. Schneider Y, Vincent F, Duranton B, Badolo L, Gosse F, Bergmann C et al: Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 158: 85-91, 2000.
53. Lu R and Serrero G: Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 179: 297-304, 1999.
54. Kampa M, Hatzoglou A, Notas G, Damianaki A, Bakogeorgou E, Gemetzi C et al: Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 37: 223-33, 2000.
55. Ding XZ and Adrian TE: Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 25: e71-6, 2002.
56. Ulsperger E, Hamilton G, Raderer M, Baumgartner G, Hejna M, Hoffmann O et al: Resveratrol pretreatment desensitizes AHTO-7 human osteoblasts to growth stimulation in response to carcinoma cell supernatants. Int J Oncol 15: 955-9, 1999.
57. Fulda S and Debatin KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64: 337-46, 2004.
58. Gao Z, Huang K, Yang X and Xu H: Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta 1472: 643-50, 1999.
59. Motoo Y and Sawabu N: Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. Cancer Lett 86 91-5, 1994.
60. Yoshimura R, Matsuyama M, Tsuchida K, Kawahito Y, Sano H and Nakatani T: Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors. J Urol 170: 1994-9, 2003.
61. Burke YD, Ayoubi AS, Werner SR, McFarland BC, Heilman DK, Ruggeri BA et al: Effects of the isoprenoids perillyl alcohol and farnesol on apoptosis biomarkers in pancreatic cancer chemoprevention. Anticancer Res 22: 3127-34, 2002.
62. Pidgeon GP, Kandouz M, Meram A and Honn KV: Mechanisms controlling cell cycle arrest and induction of apoptosis after 12-lipoxygenase inhibition in prostate cancer cells. Cancer Res 62: 2721-7, 2002.
63. Yoshimura R, Inoue K, Kawahito Y, Mitsuhashi M, Tsuchida K, Matsuyama M et al: Expression of 12-lipoxygenase in human renal cell carcinoma and growth prevention by its inhibitor. Int J Mol Med 13: 41-6, 2004.
64. Tong WG, Ding XZ, Witt RC and Adrian TE: Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 1 929-35, 2002.
65. Ding XZ, Kuszynski CA, El-Metwally TH and Adrian TE: Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Commun 266: 392-9, 1999.
66. Shapiro GI: Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res 10: 4270s-4275s, 2004.
67. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L et al: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16: 2986-99, 1998.
68. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL et al: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 92: 3804-16, 1998.
69. Jung CP, Motwani MV and Schwartz GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7: 2527-36, 2001.
70. Van Dross R, Xue Y, Knudson A and Pelling JC: The chemopreventive bioflavonoid apigenin modulates signal transduction pathways in keratinocyte and colon carcinoma cell lines. J Nutr 133 3800S-3804S, 2003.
71. Kim HP, Mani I, Iversen L and Ziboh VA: Effects of naturally-occurring flavonoids and biflavonoids on epidermal cyclooxygenase and lipoxygenase from guinea-pigs. Prostaglandins Leukot Essent Fatty Acids 58: 17-24, 1998.
72. Yin F, Giuliano AE, Law RE and Van Herle AJ: Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res 21: 413-20, 2001.
73. Wang W, Heideman L, Chung CS, Pelling JC, Koehler KJ and Birt DF: Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog 28: 102-10, 2000.
74. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M et al: Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 87: 595-600, 2000.
75. Yin F, Giuliano AE and Van Herle AJ: Growth inhibitory effects of flavonoids in human thyroid cancer cell lines. Thyroid 9 369-76, 1999.
76. Takahashi T, Kobori M, Shinmoto H and Tsushida T: Structure-activity relationships of flavonoids and the induction of granulocytic- or monocytic-differentiation in HL60 human myeloid leukemia cells. Biosci Biotechnol Biochem 62: 2199-204, 1998.
77. Ujiki MB DX, Talamonti MS, Bell RH Jr and Adrian TE: Apigenin inhibits human pancreatic cancer cell proliferation through G2/M cell cycle arrest. Pancreas 29: 334-335, 2004.
78. Ujiki MB DX, Kennedy TJ, Talamonti MS, Bell RH Jr and Adrian TE: Apigenin enhances gemcitabine-induced pancreatic cancer cell apoptosis. J Surgical Res 121: 280, 2004.
79. Punyasiri PA, Abeysinghe IS, Kumar V, Treutter D, Duy D, Gosch C et al: Flavonoid biosynthesis in the tea plant Camellia sinensis: properties of enzymes of the prominent epicatechin and catechin pathways. Arch Biochem Biophys 431: 22-30, 2004.
80. Frei B and Higdon JV: Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 133: 3275S-84S, 2003.
81. Takada M, Nakamura Y, Koizumi T, Toyama H, Kamigaki T, Suzuki Y et al: Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate. Pancreas 25: 45-8, 2002.
82. Lyn-Cook BD, Rogers T, Yan Y, Blann EB, Kadlubar FF and Hammons GJ: Chemopreventive effects of tea extracts and various components on human pancreatic and prostate tumor cells in vitro. Nutr Cancer 35: 80-6, 1999.
83. Hong J, Smith TJ, Ho CT, August DA and Yang CS: Effects of purified green and black tea polyphenols on cyclooxygenase- and lipoxygenase-dependent metabolism of arachidonic acid in human colon mucosa and colon tumor tissues. Biochem Pharmacol 62: 1175-83, 2001.
84. Kennedy TJ, Chan CY, Ding XZ and Adrian TE: Lipoxygenase inhibitors for the treatment of pancreatic cancer. Expert Rev Anticancer Ther 3: 525-36, 2003.